A human cell line derived from acute myeloid leukemia (AML). AML was originated from CMMoL. Possessing Philadelphia chromosome and t(3;3)(q21;q26). Expressing EVI1 and BCR/ABL. Application consideration
Comment from the depositor
Terms and conditions
A prior written permission of the approver(Depositor) is necessary for any kind of use including academic use and for-profit use.
RIKEN BioResource Research Center, Cell Bank, 3-1-1 Koyadai,Tsukuba-shi, Ibaraki 305-0074 Japan
Regarding MTA between user institutions and RIKEN BRC, there are two kinds of MTA, not-for-profit academic purpose (C-XXXX) and for-profit research purpose (C-XXXXp) , depending on the sort of user institutions and the purposes of use. Please use an appropriate MTA(to see). In relation to commercial use and use for patent filing, first of all Please contact RIKEN BRC (firstname.lastname@example.org).
Hamaguchi H, Suzukawa K, Nagata K, Yamamoto K, Yagasaki F, Morishita K
Establishment of a novel human myeloid leukaemia cell line (HNT-34) with t(3;3)(q21;q26), t(9;22)(q34;q11) and the expression of EVI1 gene, P210 and P190 BCR/ABL chimaeric transcripts from a patient with AML after MDS with 3q21q26 syndrome.Br J Haematol
PubMed ID: 9266939
Norio Yamakawa, Kazuko Kaneda, Yusuke Saito, Emi Ichihara, Kazuhiro Morishita
The Increased Expression of Integrin α6 (ITGA6) Enhances Drug Resistance in EVI1(high) LeukemiaPLoS One
PubMed ID: 22295105
Saito Y, Nakahata S, Yamakawa N, Kaneda K, Ichihara E, Suekane A, Morishita K.
CD52 as a molecular target for immunotherapy to treat acute myeloid leukemia with high EVI1 expression.Leukemia
PubMed ID: 21394097